Study of metronomic oral cyclophosphamide & low dose nivolumab for advanced hepatocellular carcinoma (HCC)
Latest Information Update: 20 Jul 2021
At a glance
- Drugs Cyclophosphamide (Primary) ; Nivolumab (Primary) ; Atezolizumab; Bevacizumab; Cisplatin; Lenvatinib; Pembrolizumab; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.